OLD National Bancorp IN acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 15,710 shares of the medical research company’s stock, valued at approximately $141,000.
Other hedge funds have also added to or reduced their stakes in the company. Janus Capital Management LLC acquired a new stake in NeoGenomics during the first quarter valued at $13,279,000. Tudor Investment Corp ET AL increased its stake in NeoGenomics by 69.8% in the first quarter. Tudor Investment Corp ET AL now owns 45,632 shares of the medical research company’s stock valued at $360,000 after buying an additional 18,762 shares during the period. Highbridge Capital Management LLC acquired a new stake in NeoGenomics during the first quarter valued at $531,000. Schwab Charles Investment Management Inc. increased its stake in NeoGenomics by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 198,419 shares of the medical research company’s stock valued at $1,566,000 after buying an additional 11,115 shares during the last quarter. Finally, KCG Holdings Inc. purchased a new stake in NeoGenomics during the first quarter valued at $118,000. Institutional investors and hedge funds own 82.56% of the company’s stock.
Shares of NeoGenomics, Inc. (NASDAQ:NEO) traded down 0.97% during midday trading on Friday, hitting $9.16. The stock had a trading volume of 258,607 shares. The firm has a 50 day moving average price of $9.20 and a 200 day moving average price of $8.26. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93. The stock’s market cap is $727.19 million.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.03. The company had revenue of $66.09 million during the quarter, compared to analyst estimates of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.04 earnings per share. On average, equities analysts forecast that NeoGenomics, Inc. will post $0.18 earnings per share for the current fiscal year.
Several research firms recently weighed in on NEO. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. BTIG Research restated a “buy” rating and issued a $11.00 price objective on shares of NeoGenomics in a report on Sunday, May 28th. Finally, Cantor Fitzgerald set a $11.00 target price on shares of NeoGenomics and gave the stock a “buy” rating in a report on Saturday, May 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. NeoGenomics presently has an average rating of “Buy” and an average target price of $10.40.
In related news, VP Jennifer Balliet sold 3,334 shares of the stock in a transaction on Friday, May 26th. The stock was sold at an average price of $7.50, for a total transaction of $25,005.00. Following the completion of the sale, the vice president now directly owns 10,049 shares in the company, valued at $75,367.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Alison L. Hannah acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average price of $9.19 per share, with a total value of $183,800.00. Following the completion of the acquisition, the director now owns 38,782 shares of the company’s stock, valued at approximately $356,406.58. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 84,890 shares of company stock valued at $665,707. 12.20% of the stock is owned by corporate insiders.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.